Yamakawa K - Search Results

1

Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (July 2022).

Yamakawa K, Yamamoto R, Terayama T, Hashimoto H, Ishihara T, Ishimaru G, Imura H, Okano H, Narita C, Mayumi T, Yasuda H, Yamada K, Yamada H, Kawasaki T, Shime N, Doi K, Egi M, Ogura H, Aihara M, Kushimoto S, Nishida O; Special Committee of the Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock 2020 (J‐SSCG 2020), the COVID‐19 Task Force. Yamakawa K, et al. Acute Med Surg. 2022 Oct 19;9(1):e789. doi: 10.1002/ams2.789. eCollection 2022 Jan-Dec. Acute Med Surg. 2022. PMID: 36267628 Free PMC article.

2

Production of monoclonal antibody to Clostridium difficile toxin A which neutralizes enterotoxicity but not haemagglutination activity.

Kamiya S, Yamakawa K, Meng XQ, Ogura H, Nakamura S. Kamiya S, et al. Among authors: yamakawa k. FEMS Microbiol Lett. 1991 Jul 1;65(3):311-5. doi: 10.1016/0378-1097(91)90233-z. FEMS Microbiol Lett. 1991. PMID: 1916231

3

Recovery of spores of Clostridium difficile altered by heat or alkali.

Kamiya S, Yamakawa K, Ogura H, Nakamura S. Kamiya S, et al. Among authors: yamakawa k. J Med Microbiol. 1989 Mar;28(3):217-21. doi: 10.1099/00222615-28-3-217. J Med Microbiol. 1989. PMID: 2926793

4

Haemagglutination activity of toxigenic and non-toxigenic strains of Clostridium difficile.

Meng XQ, Yamakawa K, Ogura H, Nakamura S. Meng XQ, et al. Among authors: yamakawa k. FEMS Microbiol Lett. 1994 May 1;118(1-2):141-4. doi: 10.1111/j.1574-6968.1994.tb06816.x. FEMS Microbiol Lett. 1994. PMID: 8013869

5

Immunological comparison of intracellular toxin A and extracellular toxin A from Clostridium difficile.

Meng XQ, Yamakawa K, Ogura H, Nakamura S. Meng XQ, et al. Among authors: yamakawa k. Jpn J Med Sci Biol. 1993 Feb;46(1):51-6. doi: 10.7883/yoken1952.46.51. Jpn J Med Sci Biol. 1993. PMID: 8230809

6

Purification and characterisation of intracellular toxin A of Clostridium difficile.

Meng XQ, Kamiya S, Yamakawa K, Ogura H, Nakamura S. Meng XQ, et al. Among authors: yamakawa k. J Med Microbiol. 1993 Jan;38(1):69-73. doi: 10.1099/00222615-38-1-69. J Med Microbiol. 1993. PMID: 8418298

7

A novel technique of differential lung ventilation in the critical care setting.

Yamakawa K, Nakamori Y, Fujimi S, Ogura H, Kuwagata Y, Shimazu T. Yamakawa K, et al. BMC Res Notes. 2011 May 5;4:134. doi: 10.1186/1756-0500-4-134. BMC Res Notes. 2011. PMID: 21545715 Free PMC article.

8

Systemic involvement of high-mobility group box 1 protein and therapeutic effect of anti-high-mobility group box 1 protein antibody in a rat model of crush injury.

Shimazaki J, Matsumoto N, Ogura H, Muroya T, Kuwagata Y, Nakagawa J, Yamakawa K, Hosotsubo H, Imamura Y, Shimazu T. Shimazaki J, et al. Among authors: yamakawa k. Shock. 2012 Jun;37(6):634-8. doi: 10.1097/SHK.0b013e31824ed6b7. Shock. 2012. PMID: 22392147

9

Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis.

Ogawa Y, Yamakawa K, Ogura H, Kiguchi T, Mohri T, Nakamori Y, Kuwagata Y, Shimazu T, Hamasaki T, Fujimi S. Ogawa Y, et al. Among authors: yamakawa k. J Trauma Acute Care Surg. 2012 May;72(5):1150-7. doi: 10.1097/TA.0b013e3182516ab5. J Trauma Acute Care Surg. 2012. PMID: 22673239

10

Platelet mitochondrial membrane potential correlates with severity in patients with systemic inflammatory response syndrome.

Yamakawa K, Ogura H, Koh T, Ogawa Y, Matsumoto N, Kuwagata Y, Shimazu T. Yamakawa K, et al. J Trauma Acute Care Surg. 2013 Feb;74(2):411-7; discussion 418. doi: 10.1097/TA.0b013e31827a34cf. J Trauma Acute Care Surg. 2013. PMID: 23354232

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,133 results

Search Page

Filters